PT2748165T - Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas - Google Patents

Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas

Info

Publication number
PT2748165T
PT2748165T PT127728087T PT12772808T PT2748165T PT 2748165 T PT2748165 T PT 2748165T PT 127728087 T PT127728087 T PT 127728087T PT 12772808 T PT12772808 T PT 12772808T PT 2748165 T PT2748165 T PT 2748165T
Authority
PT
Portugal
Prior art keywords
octan
diazabicyclo
derivatives
treatment
bacterial infections
Prior art date
Application number
PT127728087T
Other languages
English (en)
Portuguese (pt)
Inventor
Vithalbhai Patel Mahesh
Alam Jafri Mohammad
Keshav Deshpande Prasad
Bhawsar Satish
Bhagwat Sachin
Mishra Amit
Pavase Laxmikant
Gupta Sunil
Kale Rajesh
Joshi Sanjeev
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of PT2748165T publication Critical patent/PT2748165T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT127728087T 2011-08-27 2012-08-24 Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas PT2748165T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2412MU2011 2011-08-27

Publications (1)

Publication Number Publication Date
PT2748165T true PT2748165T (pt) 2016-12-28

Family

ID=54289195

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127728087T PT2748165T (pt) 2011-08-27 2012-08-24 Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas

Country Status (17)

Country Link
US (5) US8822450B2 (enExample)
EP (1) EP2748165B1 (enExample)
JP (1) JP5666743B2 (enExample)
KR (1) KR101512738B1 (enExample)
CN (1) CN103619843B (enExample)
AU (1) AU2012303691B2 (enExample)
BR (1) BR112013028813B1 (enExample)
CA (1) CA2833241C (enExample)
DK (1) DK2748165T3 (enExample)
ES (1) ES2603198T3 (enExample)
HU (1) HUE030311T2 (enExample)
MX (1) MX348974B (enExample)
PL (1) PL2748165T3 (enExample)
PT (1) PT2748165T (enExample)
RU (2) RU2636147C1 (enExample)
WO (1) WO2013030733A1 (enExample)
ZA (1) ZA201307631B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6179588A (ja) * 1984-09-28 1986-04-23 株式会社東芝 多関節ロボツト
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
CN107854477A (zh) 2008-10-24 2018-03-30 森普拉制药公司 使用含三唑的大环内酯治疗抗性疾病的方法
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
BR112013028813B1 (pt) * 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
AU2014206087A1 (en) * 2013-01-14 2015-05-28 Wockhardt Limited Compositions and methods for treating bacterial infections
BR112015021186A2 (pt) * 2013-03-08 2017-07-18 Wockhardt Ltd processo para a preparação de (2s,5r)-7-oxo-6-sulfóxi-2-[((3r)-pirrolidina-3-carbonil)-hidrazino carbonil]-1,6-diaza-biciclo[3.2.1]octano
WO2014135931A1 (en) * 2013-03-08 2014-09-12 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
AU2013380574B2 (en) * 2013-03-08 2016-07-07 Wockhardt Limited A process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2-[((3R)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
KR101774132B1 (ko) * 2013-03-08 2017-09-01 욱크하르트 리미티드 (2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피페리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]-옥탄의 제조 방법
WO2014152326A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
US20140275000A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
AU2014233240B2 (en) 2013-03-15 2018-08-09 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
DK3050883T3 (da) 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
CN105612159A (zh) 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
WO2015059643A1 (en) * 2013-10-22 2015-04-30 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
CN106163519A (zh) * 2013-10-30 2016-11-23 沃克哈特有限公司 包含抗菌剂的药物组合物
RU2705375C2 (ru) * 2014-01-21 2019-11-07 Вокхардт Лимитед Фармацевтические композиции, содержащие антибактериальные агенты
WO2015110885A1 (en) * 2014-01-21 2015-07-30 Wockhardt Limited A process for preparation of (2s,5r)-6-sulphooxy-7-oxo-2-[((3r)-piperidine-3-carbonyl)-hydrazinocarbonyl]-1,6-diaza-bicyclo[3.2.1] octane
CN106211771A (zh) * 2014-01-21 2016-12-07 沃克哈特有限公司 含氮化合物及其作为抗菌剂的用途
EP3125887A1 (en) * 2014-03-29 2017-02-08 Wockhardt Limited Pharmaceutical compositions comprising cefepime or sulbactam
EP3131583A1 (en) * 2014-04-18 2017-02-22 The Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
EP3185864A4 (en) * 2014-08-05 2018-03-28 Cempra Pharmaceuticals, Inc. Powder oral suspension formulations of antibacterial agents
TWI690317B (zh) 2014-11-17 2020-04-11 英商安特西醫療有限公司 用於治療抗藥性細菌感染之組合療法
SG11201704576SA (en) 2014-12-05 2017-07-28 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
WO2016116788A1 (en) * 2015-01-24 2016-07-28 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2016151543A1 (en) * 2015-03-25 2016-09-29 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
EP3075734A1 (en) * 2015-03-31 2016-10-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
HK1244791A1 (zh) 2015-03-31 2018-08-17 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
WO2017002089A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002083A1 (en) * 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002086A1 (en) * 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
CA2984024A1 (en) * 2015-09-16 2017-03-23 Xuanzhu Pharma Co., Ltd. .beta.-lactamase inhibitors and uses thereof
CN108137567A (zh) 2015-10-02 2018-06-08 乐高化学生物科学股份有限公司 用于抑制β-内酰胺酶的组合物和方法
US20190077802A1 (en) * 2015-10-06 2019-03-14 Wockhardt Limited Difluoro-(2-substituted carbamoyl-1,6-diaza-bicyclo [3.2.1] oct-6-yloxy) acetic acid compounds and their use in treatment of bacterial infections
WO2017081615A1 (en) 2015-11-09 2017-05-18 Wockhardt Limited 7-oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections
DE102016005299A1 (de) * 2016-05-02 2017-11-02 Eisele Pneumatics Gmbh & Co. Kg Verfahren zum Herstellen eines gebogenen rohrförmigen Verbindungselementes
WO2017216764A1 (en) * 2016-06-17 2017-12-21 Wockhardt Limited N-(alkanoyl)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carbonylhydrazide derivatives and their use as antibacterial agents
SG11201901658PA (en) * 2016-09-16 2019-04-29 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
WO2018141991A1 (en) * 2017-02-06 2018-08-09 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
EA037916B1 (ru) * 2017-02-08 2021-06-07 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
KR102354697B1 (ko) * 2017-03-02 2022-01-21 욱크하르트 리미티드 항박테리아 화합물로서의 헤테로고리 유도체
PT3630111T (pt) 2017-05-08 2022-03-01 Entasis Therapeutics Inc Compostos e métodos de tratamento de infeções bacterianas
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited Process for o-sulfonation of 1,6-diazabicyclo[3.2.1]octane compounds
US11180501B2 (en) 2017-12-01 2021-11-23 Qilu Pharmaceutical Co., Ltd. Crystal form of β-lactamase inhibitor and preparation method therefor
WO2022047603A1 (en) * 2020-09-01 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Beta-lactamase inhibitors and their preparation
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306833D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
CN117700415B (zh) * 2024-02-06 2024-04-30 成都四面体药物研究有限公司 含脲双环化合物、其用途、其制备的药物、其联合用药物及其复方制剂
WO2026104587A1 (en) 2024-11-13 2026-05-21 Adjutec Pharma As Cyclic boronic acid esters useful as adjuvants in the treatment of bacterial infections

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0607164B1 (en) * 1991-09-26 2002-05-02 Pfizer Inc. Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
ATE177099T1 (de) * 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP5038509B2 (ja) * 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
BR112013028813B1 (pt) * 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem

Also Published As

Publication number Publication date
US20150174133A1 (en) 2015-06-25
BR112013028813B1 (pt) 2020-10-20
AU2012303691A1 (en) 2013-10-31
EP2748165B1 (en) 2016-11-02
US8853197B1 (en) 2014-10-07
NZ616542A (en) 2015-01-30
JP5666743B2 (ja) 2015-02-12
ZA201307631B (en) 2014-12-23
CA2833241C (en) 2015-05-12
MX348974B (es) 2017-07-04
US8822450B2 (en) 2014-09-02
MX2013013887A (es) 2014-01-24
RU2636147C1 (ru) 2017-11-21
US20150328201A1 (en) 2015-11-19
CN103619843A (zh) 2014-03-05
US20140275018A1 (en) 2014-09-18
RU2013155902A (ru) 2015-10-10
CA2833241A1 (en) 2013-03-07
JP2014515041A (ja) 2014-06-26
US9381200B2 (en) 2016-07-05
US20150005285A1 (en) 2015-01-01
WO2013030733A1 (en) 2013-03-07
RU2578370C2 (ru) 2016-03-27
AU2012303691B2 (en) 2014-06-19
EP2748165A1 (en) 2014-07-02
DK2748165T3 (en) 2016-12-19
KR101512738B1 (ko) 2015-04-17
US8987297B2 (en) 2015-03-24
KR20140025525A (ko) 2014-03-04
HUE030311T2 (en) 2017-04-28
CN103619843B (zh) 2017-01-11
US9132133B2 (en) 2015-09-15
BR112013028813A2 (pt) 2017-01-31
US20140148431A1 (en) 2014-05-29
ES2603198T3 (es) 2017-02-24
PL2748165T3 (pl) 2017-05-31

Similar Documents

Publication Publication Date Title
PL2748165T3 (pl) Pochodne 1,6-diazabicyklo[3,2,1]oktan-7-onu i ich zastosowanie w leczeniu zakażeń bakteryjnych
PT2872510T (pt) Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infeções bacterianas
ZA201500970B (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
WO2011113606A8 (en) Anti-infective compounds
IL221160A (en) 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation
WO2011085990A8 (en) Anti - infective pyrido (1,2 -a) pyrimidines
PL2739615T3 (pl) Fenylo-3-aza-bicyklo[3.1.0]heks-3-ylo-metanony i ich zastosowanie jako leki
IL238493B (en) Amino-substituted imidazo[a–2,1]pyridinecarboxamides and their use
IL216723A0 (en) 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer
PL2736488T3 (pl) Kompozycje farmaceutyczne zawierające rifaksyminę, sposoby ich wytwarzania i ich zastosowanie do leczenia zakażeń pochwy
SI2575971T1 (sl) Kombinirani rastlinski izvlečki za uporabo pri zdravljenju okužb z mikrobi
PL2726470T3 (pl) Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych
ZA201303829B (en) 2-piperazin-1-yl-4h-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections
HK1201836A1 (en) Novel pyrrole derivatives
HK1219690A1 (zh) 利用抗生素来治疗超重和肥胖患者感染的方法
SI2683418T1 (sl) Produkti za vezavo bakterijskih toksinov in njihovo odstranjevanje pri zdravljenju lokalnih okužb in izdelava le-teh
SI2699545T1 (sl) Novi amino-pirolinski derivati in uporaba le-teh pri preprečevanju in/ali zdravljenju metaboličnega sindroma
WO2012146736A8 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
IL226939A (en) Diarylpyridazinone derivatives, their preparation, and their use in the treatment of humans
HU1000356D0 (en) Quinoxaline derivatives and their use for the treatment of mycobacterial infections
PL2797914T3 (pl) Sulfotlenek nifuratelu do zastosowania w leczeniu infekcji bakteryjnych
HK1196617A (en) Novel purine derivatives and their use in the treatment of disease